These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18172042)

  • 1. Letter by de Boer and van Veldhuisen regarding article, "Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)".
    de Boer RA; van Veldhuisen DJ
    Circulation; 2008 Jan; 117(1):e7; author reply e8. PubMed ID: 18172042
    [No Abstract]   [Full Text] [Related]  

  • 2. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
    Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial.
    Uretsky BF; Thygesen K; Daubert JC; Erdmann E; Freemantle N; Gras D; Kappenberger L; Tavazzi L; Cleland JG
    J Card Fail; 2008 Oct; 14(8):670-5. PubMed ID: 18926439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.
    Sweeney MO; Hellkamp AS; Ellenbogen KA; Lamas GA
    J Cardiovasc Electrophysiol; 2008 Nov; 19(11):1160-6. PubMed ID: 18554201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias.
    Chapa DW; Lee HJ; Kao CW; Friedmann E; Thomas SA; Anderson J; Bardy GH
    Am J Crit Care; 2008 Sep; 17(5):443-52; quiz 453. PubMed ID: 18776000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-wave alternans in the sudden cardiac death in heart failure trial population: signal or noise?
    Rosenbaum DS
    Circulation; 2008 Nov; 118(20):2015-8. PubMed ID: 19001031
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by De Ferrari and Verrier regarding article, "Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy".
    De Ferrari GM; Verrier RL
    Circulation; 2009 Jul; 120(3):e20; author reply e22. PubMed ID: 19620521
    [No Abstract]   [Full Text] [Related]  

  • 8. Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.
    Kuch M; Janiszewski M; Mamcarz A; Cudnoch-Jedrzejewska A; Dłuzniewski M
    Med Sci Monit; 2009 Jun; 15(6):PH40-8. PubMed ID: 19478711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we use anticoagulation for patients with chronic heart failure?
    Freudenberger RS; Halperin JL
    Nat Clin Pract Cardiovasc Med; 2006 Nov; 3(11):580-1. PubMed ID: 17063158
    [No Abstract]   [Full Text] [Related]  

  • 10. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
    Vrtovec B; Okrajsek R; Golicnik A; Ferjan M; Starc V; Schlegel TT; Radovancevic B
    J Card Fail; 2008 Mar; 14(2):140-4. PubMed ID: 18325461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter by Höglund and Nilsson regarding article, "influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure".
    Höglund P; Nilsson LA
    Circulation; 2008 Jul; 118(1):e7; author reply e8. PubMed ID: 18591445
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter by Madias regarding article, "Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy".
    Madias JE
    Circulation; 2009 Jul; 120(3):e21; author reply e22. PubMed ID: 19620522
    [No Abstract]   [Full Text] [Related]  

  • 14. [The embolic risk and oral anticoagulant therapy in chronic heart failure].
    Urbinati S; Pinelli G; Maggioni AP; Zaccaroni S; Gorini M; Lucci D
    G Ital Cardiol; 1999 Feb; 29(2):183-92. PubMed ID: 10088077
    [No Abstract]   [Full Text] [Related]  

  • 15. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
    Das M
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticoagulation in chronic heart failure and left ventricular dysfunction].
    Wichter T; Breithardt G
    Dtsch Med Wochenschr; 2002 Oct; 127(41):2145-8. PubMed ID: 12397561
    [No Abstract]   [Full Text] [Related]  

  • 18. What do we know about anticoagulation in patients with heart failure?
    Ahnert AM; Freudenberger RS
    Curr Opin Cardiol; 2008 May; 23(3):228-32. PubMed ID: 18382211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
    Ding L; Hua W; Niu H; Chen K; Zhang S
    Europace; 2008 Sep; 10(9):1034-41. PubMed ID: 18559335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.